"My child is very short — can I give them growth hormone?" One of the most common questions for pediatric endocrinologists. The answer is complex — indications must be clear, the cost is high, follow-up is strict. Here's the full 2026 picture of GH therapy.
What is growth hormone (GH)?
GH is a protein hormone called somatotropin, secreted by the pituitary. It stimulates IGF-1 in the liver, which acts directly on cartilage at the growth plates and lengthens bone.
Natural GH:
- Pulsatile secretion
- Highest at sleep onset (first 3 hours)
- Peaks during puberty
- Decreases in adulthood but continues lifelong
Synthetic GH (somatropin)
Produced via recombinant DNA technology since 1985. Older "cadaver-derived" GH was banned due to Creutzfeldt-Jakob disease risk.
Brand examples: Genotropin, Norditropin, Saizen, Humatrope, Omnitrope.
Form: daily subcutaneous injection (pre-sleep). Newer long-acting versions are weekly (Sogroya, Skytrofa, Ngenla — approved 2023-2024).
Approved indications (FDA + EMA)
GH therapy isn't prescribed for any short stature. Indications:
1. Growth hormone deficiency (GHD)
- ~30-40% of pediatric cases
- Diagnosis: 2 different GH stimulation tests + low IGF-1 + height <p3
- Strongest responder group
2. Turner syndrome
- Girls with XO karyotype
- Untreated adult height ~143 cm; GH adds ~7-12 cm
- Usually started at age 4-6
3. SGA (Small for Gestational Age)
- Birth height/weight <p3 with no catch-up by age 4
- GH adds +1 SD of height
4. Prader-Willi syndrome
- Genetic deletion (chromosome 15q11-q13)
- GH corrects both height and body composition (fat/muscle ratio)
5. Chronic kidney disease
- Pre- and post-dialysis, transplant candidates
6. Idiopathic Short Stature (ISS)
- All pathology excluded, height <p1 (i.e., −2.25 SD below)
- Approved in the US, contested in some European countries
- Turkey: SGK does not cover (off-label)
7. Noonan syndrome
- RAS pathway mutation, moderate response
Coverage by Turkey's SGK
SGK covers:
- GH deficiency (test-documented)
- Turner syndrome
- SGA (age ≥4, no catch-up)
- Prader-Willi
- CKD
SGK does not cover:
- ISS (Idiopathic Short Stature)
- Familial short stature (even if <p3)
- Cosmetic height-boost requests
Out-of-pocket monthly cost: $800-1,500 (5,000-9,000 TL at 2026 exchange).
Treatment course
Start age
Ideal: age 4-9. Earlier start → higher total height gain.
Dose
0.025-0.05 mg/kg/day. Adolescents may go up to 0.07 mg/kg.
Duration
Generally until puberty completes — 4-12 years of therapy. Girls reach the endpoint around 14-15; boys 16-17.
Follow-up
- Every 3 months: height + weight + IGF-1
- Every 6 months: thyroid + glucose + insulin
- Yearly: hand-wrist x-ray (bone age)
- Continue until adult bone age, not by chronological age
Success criteria
Ideal response (responder):
- First-year height gain +8-12 cm (in GHD)
- First-year +0.5 SD height z-score
- IGF-1 levels in p50-95 for age and sex
Low response (poor responder):
- First year <+0.3 SD
- Likely causes: noncompliance, IGF-1 resistance, malnutrition
Stop criteria:
- Growth velocity <2 cm/yr
- Adult BA reached
- Family unable to afford (common scenario)
- Side effect development
Side effects
Common (mild)
- Injection-site reactions
- Transient headaches
- Transient joint pain
- Mild nausea
Rare but watchful
- Idiopathic intracranial hypertension (IIH) — severe headache + visual changes; therapy halted
- Slipped capital femoral epiphysis (SCFE) — hip pain
- Worsening scoliosis — especially in Turner syndrome
- Insulin resistance — long-term glucose monitoring needed
Debated (long-term)
- Cancer risk: Older studies showed leukemia/colorectal links. Newer meta-analyses (2020+) show no added risk in healthy children — but caution is warranted in those with prior cancer.
- Cardiovascular: Long-term data limited.
Cost/benefit
- Pre-treatment MPH: 158 cm
- After 8 years of therapy: ~168 cm expected
- Gain: 10 cm
- Total cost (if SGK doesn't cover): 8 yrs × $12,000 = $96,000
Roughly $10,000 per cm. This economic decision belongs to the family.
FAQ
Does GH therapy extend lifespan?
No, it only affects height. Lifespan-neutral. But untreated GHD has metabolic consequences and may raise long-term mortality.
Is there adult GH deficiency?
Yes — some adults develop GHD (panhypopituitarism, trauma, post-tumor). But adult treatment focuses on body composition + metabolism, not height.
My child is at p3 but all tests are normal — can they get GH?
SGK won't cover (no ISS indication in Turkey). Private pay is possible with pediatric endocrinology approval. Cost/benefit must be considered carefully.
Can my child exercise during therapy?
Yes — encouraged. Only avoid traumatic sports (boxing) due to SCFE risk.
Bottom line
GH therapy is safe and effective with a documented indication + endocrinology follow-up. It corrects pathology, not cosmetic shortness. For science-based decision-making, systematically track all growth data — sign up free, log measurements, and use PDF + Excel exports to bring to your pediatric endocrinologist when needed.